Ketamine Therapy in Canada: Pros, Cons, Trends, and How to Choose a Clinic

01

Ketamine, esketamine, and off-label care are different conversations

Ketamine is a dissociative anesthetic and a Schedule I controlled substance in Canada. Health Canada authorizes ketamine injection as a general anesthetic for humans. When a clinician proposes ketamine injection for depression or another mental-health condition, that is an off-label use: the drug is authorized, but not for that particular indication or set of conditions. Health Canada states that it has not assessed the benefits and risks of ketamine for off-label conditions, including the various formulations and compounded products that have attracted increased interest.

Esketamine is related to ketamine but is not interchangeable with every ketamine service. Health Canada authorized the intranasal product Spravato for specified adults with moderate-to-severe major depressive disorder that did not respond to other antidepressant courses. Federal information describes controlled distribution plus requirements for administration and post-administration monitoring by a healthcare professional. Ask a clinic to name the drug, formulation, route, proposed indication, and whether the proposed use follows an authorized product indication or is off-label.

• Ketamine injection: authorized in Canada as a general anesthetic; psychiatric use is off-label.
• Intranasal esketamine: a distinct prescription product with a specific depression indication and monitoring requirements.
• Psychotherapy: a separate service that needs its own qualified provider, consent process, goals, and follow-up.

Learn more: Health Canada: Ketamine • Health Canada Health Product InfoWatch: Ketamine off-label use • Health Canada: Drugs and medical devices approved in 2020, including Spravato

02

Why ketamine therapy is trending in Canada

Several forces are driving attention. Many people live with depression that has not improved enough after established medication and psychotherapy. Health Canada’s Scientific Advisory Committee notes that intravenous ketamine and intranasal esketamine have been considered in cases of treatment resistance, alongside other interventional options. The committee also identifies barriers involving funding, geography, stigma, service availability, and access to psychiatric input. Private clinics and media coverage have grown into some of that gap, while current Canadian trials show that research remains active rather than settled.

The trend also deserves consumer caution. The federal advisory committee warns that direct-to-consumer business models can use unsubstantiated claims or templated access to experimental medication, potentially drawing people away from established care. Popularity, polished branding, testimonials, and a long waiting list are not substitutes for psychiatric assessment, balanced consent, documented alternatives, and outcome monitoring.

• Growing interest does not make all protocols equivalent.
• A registered trial is evidence of ongoing research, not proof for an unrelated clinic service.
• Marketing quality tells you little about clinical quality.

Learn more: Health Canada Scientific Advisory Committee on Mental Health Disorders: Consensus statements • Health Canada Health Product InfoWatch: Ketamine off-label use • Health Canada clinical trial portal: Intravenous ketamine and virtual reality for depression

03

Potential pros: why a qualified clinician may consider it

One potential advantage is that ketamine and esketamine create an additional clinical pathway when appropriate established care has not produced enough improvement. Health Canada’s advisory committee discusses intravenous ketamine and intranasal esketamine in treatment-resistant cases and recognizes them among interventional options. For a carefully assessed patient, having another option can matter, particularly when previous medication courses, psychotherapy, adherence, dose, duration, diagnosis, and comorbidities have been reviewed rather than assumed.

Ketamine is fast acting as a drug, which contributes to clinical and public interest. That phrase needs discipline: fast pharmacological action is not a guarantee of immediate, complete, or lasting improvement in mood. Response differs among people, and benefits may fade or require a broader maintenance plan. A responsible clinic should describe realistic goals, the measures it uses to track change, when it decides the approach is not helping, and which continuing treatments support care between visits.

• A possible option after appropriate reassessment and prior adequate care.
• A structured setting where response and adverse effects can be observed.
• An opportunity to connect medication decisions with follow-up, psychotherapy, and an existing care team.

Learn more: Health Canada Scientific Advisory Committee on Mental Health Disorders: Consensus statements • Health Canada: Ketamine • Health Canada Health Product InfoWatch: Ketamine off-label use

04

Cons: risks, costs, repeated visits, and uncertainty

Ketamine has significant short-term risks. Health Canada lists sleepiness, confusion, loss of coordination, dissociation, hallucinations, nausea, vomiting, increased blood pressure and heart rate, difficulty breathing, and loss of consciousness among possible effects. Sedation and altered awareness affect driving and other activities that require attention. Co-use with alcohol, opioids, or other depressants can raise the risk of respiratory depression. A clinic should give individualized preparation and transportation instructions rather than relying on a generic website FAQ.

Repeated or chronic exposure adds other concerns. Federal safety information reports abuse and misuse potential, urinary and bladder problems, and hepatobiliary toxicity. Health Canada also notes that regular use can lead to tolerance, addiction, and withdrawal symptoms. These facts do not mean every medically supervised patient will experience those outcomes, but they support screening, dose and frequency documentation, symptom review, and a plan that avoids open-ended treatment without reassessment.

Off-label care adds evidence and protocol uncertainty. Health Canada has not assessed the risks and benefits of ketamine for off-label conditions, and clinics may differ in route, dose, visit schedule, psychological support, monitoring, and maintenance. Financial cost can compound that uncertainty because private care may involve assessment fees, a series of sessions, transportation, time away from work, psychotherapy, and follow-up. Ask for the total expected cost, alternatives, stopping rules, and refund or cancellation terms before committing.

• Immediate effects may impair awareness, coordination, blood pressure, breathing, and the ability to drive.
• Repeated exposure raises concerns about misuse, tolerance, bladder or urinary problems, and liver or bile-duct injury.
• Private costs, travel, repeated appointments, uncertain durability, and opportunity costs belong in the decision.

Learn more: Health Canada: Ketamine • Health Canada Health Product InfoWatch: Ketamine off-label use • Health Canada Scientific Advisory Committee on Mental Health Disorders: Consensus statements

05

Who can prescribe, administer, and monitor ketamine therapy?

There is no single Canada-wide job title that answers every version of this question. Ketamine is controlled federally, while provinces and territories regulate healthcare practice, facilities, and professional scope. Health Canada’s controlled-substance policy describes practitioners as including physicians and, in some circumstances, nurse practitioners and certain other regulated professions. It also describes conditions under which nurses may handle or administer controlled substances pursuant to an authorized order. Local law, employer policy, product requirements, route, setting, and the professional’s individual scope all matter.

The prescriber, person administering or supervising the medication, monitor, and psychotherapy provider may be different people. For esketamine, Health Canada describes a controlled distribution program and healthcare-professional administration and post-administration monitoring requirements. For off-label ketamine, ask who accepts medical responsibility, who is physically present, what each team member is licensed to do, and what emergency skills and equipment are available. “Clinician supervised” is too vague without names and roles. Verify registrations through the relevant provincial or territorial college and ask whether a psychiatrist participates in assessment or consultation.

• Request the full name, profession, licence jurisdiction, and role of each responsible provider.
• Confirm who can respond to a medical or psychiatric problem during and after the appointment.
• Ask how the clinic communicates with your primary-care or mental-health team, with your consent.

Learn more: Health Canada: Transportation and handling of controlled substances in Canada • Health Canada Health Product InfoWatch: Ketamine off-label use • Health Canada Scientific Advisory Committee on Mental Health Disorders: Consensus statements

06

Contacting a local ketamine therapy clinic: a practical checklist

You can contact a local clinic for information without agreeing to care. Start by asking for written answers or a consultation with the responsible prescriber, not only a sales coordinator. Share enough information for appropriate screening, but do not send extensive medical records through an unsecured form. A credible clinic should be willing to explain what it offers, where authorization ends and off-label practice begins, how it assesses eligibility, and which situations require another level of care.

Listen for balanced language. Be cautious if staff promise a cure, guarantee rapid results, minimize dissociation or cardiovascular effects, sell a large package before medical assessment, discourage contact with your existing clinicians, or cannot identify who holds clinical responsibility. Health Canada warns that direct-to-consumer models and unsubstantiated claims may move vulnerable patients away from established care. Pressure and urgency are not signs of a better protocol.

• Ask questions before paying for a multi-session package.
• Get the proposed drug, route, indication, monitoring, and full cost in writing.
• Verify provider registrations independently and request coordination with your current care team.

Learn more: Health Canada Scientific Advisory Committee on Mental Health Disorders: Consensus statements • Health Canada Health Product InfoWatch: Ketamine off-label use • Health Canada: Ketamine

07

Preparing, following up, and knowing when care is urgent

If you proceed after qualified assessment, follow the clinic’s individualized instructions about food, drink, regular medications, transportation, and support after the visit. Do not change prescribed medication or combine substances based on general online advice. Arrange a ride if required, keep the remainder of the day clear, and know whom to call about unexpected symptoms. Ask for written discharge instructions before the first medication appointment rather than when you are recovering from an altered state.

A commercial clinic is not automatically a crisis service. If you are in immediate danger, have severe breathing difficulty, lose consciousness, or face another urgent medical problem, call 9-1-1 or go to the nearest emergency department. If you are thinking about suicide or worried about someone who is, call or text 9-8-8 anywhere in Canada. Federal mental-health resources can also help locate provincial, territorial, Indigenous, youth, veteran, and community supports.

• Get preparation, transportation, discharge, and after-hours instructions in writing.
• Track both benefit and harm; decide in advance what triggers reassessment or stopping.
• Use 9-1-1 for immediate danger or urgent medical help and 9-8-8 for suicide crisis support.

Learn more: Health Canada: Ketamine • Government of Canada: Mental health support • Government of Canada: What Canada is doing to help prevent suicide